Teraliv 275, 275 mg 24 pcs

A nonsteroidal anti-inflammatory drug.

The drug Teraliv 275 is naproxen, has analgesic, antipyretic and anti-inflammatory effects. The mechanism of action is associated with non-selective inhibition of cyclooxygenase-1 and -2 (COX-1, COX-2) activity.

The drug Teraliv 275, film-coated tablets dissolves well, is quickly absorbed from the gastrointestinal tract and provides rapid onset of analgesic effect.

Indications

Diseases of the musculoskeletal system (rheumatic lesions of soft tissues, osteoarthritis of peripheral joints and spine, including radicular syndrome, tenosynovitis, bursitis).

Pain syndrome of mild or moderate severity: neuralgia, ossalgia, myalgia, lumboischialgia, post-traumatic pain syndrome (sprains and bruises), accompanied by inflammation, headache, migraine, algodismenorrhea, toothache.

As part of complex therapy for infectious and inflammatory diseases of the ear, nose and throat with severe pain (pharyngitis, tonsillitis, otitis media).

Feverish syndrome with “colds” and infectious diseases.

Theraliv 275 is used for symptomatic therapy (to reduce pain, inflammation and fever) and does not affect the progression of the underlying disease.

Pharmacological effect

Non-steroidal anti-inflammatory drug.

The drug Teraliv 275 is naproxen, has analgesic, antipyretic and anti-inflammatory effects. The mechanism of action is associated with non-selective inhibition of the activity of cyclooxygenase-1 and -2 (COX-1, COX-2).

The drug Theraliv 275, film-coated tablets, dissolves well, is quickly absorbed from the gastrointestinal tract and provides a rapid onset of analgesic effect.

Special instructions

Do not exceed the doses specified in the instructions. To reduce the risk of developing adverse events from the gastrointestinal tract, the minimum effective dose should be used for the shortest possible short course.

If pain and fever persist or get worse, you should see a doctor. Patients with bronchial asthma, bleeding disorders, as well as patients with hypersensitivity to other analgesics should consult a doctor before taking Theraliv 275.

Caution should be used in patients with liver disease and renal failure. In patients with renal failure, creatinine clearance should be monitored. When CC is less than 30 ml/min, the use of naproxen is not recommended. In chronic alcoholism and other forms of liver cirrhosis, the concentration of unbound naproxen increases, so lower doses are recommended for such patients. After two weeks of using the drug, monitoring of liver function indicators is necessary.

Theraliv 275 should not be taken together with other anti-inflammatory or painkillers, unless prescribed by a doctor.

Lower doses are also recommended for elderly patients.

Naproxen should be avoided within 48 hours before surgery. If it is necessary to determine 17-corticosteroids, the drug should be discontinued 48 hours before the study. Similarly, naproxen may affect the determination of 5-hydroxyindoleacetic acid in urine.

The use of naproxen, like other drugs that block prostaglandin synthesis, may affect fertility and is therefore not recommended for women planning pregnancy.

Each tablet of Theraliv 275 contains approximately 25 mg of sodium. When limiting salt intake, this must be taken into account.

Impact on the ability to drive vehicles and machinery

Naproxen slows down the reaction rate in patients. This should be taken into account when driving and performing tasks that require increased attention.

Active ingredient

Naproxen

Composition

1 tablet contains

Active ingredient:

naproxen sodium 275 mg.

Excipients:

microcrystalline cellulose 55.00 mg,

povidone K-30 12.50 mg,

talc 15.75 mg,

magnesium stearate 2.63 mg;

film cover:

opadry blue YS-1-4215 9 mg:

macrogol 8000,

indigo carmine,

titanium dioxide,

hypromellose.

Contraindications

Hypersensitivity to naproxen or naproxen sodium.

Complete or incomplete combination of bronchial asthma, recurrent nasal polyposis or paranasal sinuses and intolerance to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs (NSAIDs) (including a history).

The period after coronary artery bypass surgery.

Erosive and ulcerative changes in the mucous membrane of the stomach or duodenum, active gastrointestinal bleeding.

Inflammatory bowel diseases (ulcerative colitis, Crohn’s disease) in the acute phase.

Hemophilia and other bleeding disorders and hemostasis disorders.

Cerebrovascular bleeding or other bleeding.

Decompensated heart failure.

Severe liver failure or active liver disease.

Severe renal failure (creatinine clearance (CC) less than 30 ml/min), progressive kidney disease, confirmed hyperkalemia.

Pregnancy, breastfeeding period.

Children under 15 years of age.

With caution

Coronary heart disease, cerebrovascular disease, congestive heart failure, dyslipidemia/hyperlipidemia, diabetes mellitus, peripheral arterial disease, smoking, impaired renal function (creatinine clearance 30-60 ml/min), history of ulcerative lesions of the gastrointestinal tract (GIT), presence of Helicobacter pylori infection, use in elderly patients, systemic lupus erythematosus or mixed connective tissue diseases (Sharp’s syndrome), long-term use of NSAIDs, frequent alcohol consumption, severe somatic diseases, concomitant therapy with the following drugs: anticoagulants (for example, warfarin), antiplatelet agents (for example, acetylsalicylic acid, clopidogrel), oral glucocorticoids (for example, prednisolone), selective serotonin reuptake inhibitors (for example, citalopram, fluoxetine, paroxetine, sertraline).

Side Effects

Adverse effects that may occur during treatment with naproxen are classified according to the following frequencies: very common (> 1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (< 1/10000), frequency unknown (cannot be determined from available data).

Gastrointestinal disorders: the most frequently observed adverse events were gastrointestinal. Peptic ulcers, perforation or gastrointestinal bleeding may develop, sometimes fatal, especially in elderly patients (see section “Special Instructions”).

Within each group, adverse events are listed in descending order of severity.

Blood and lymphatic system disorders

Uncommon: eosinophilia, granulocytopenia, leukopenia, thrombocytopenia.

Nervous system disorders

Common: headache, vertigo, dizziness, drowsiness.

Uncommon: depression, sleep disturbances, inability to concentrate, insomnia, malaise.

Visual disorders

Common: blurred vision.

Hearing and labyrinth disorders

Common: tinnitus, hearing loss.

Uncommon: hearing loss.

Heart disorders

Common: swelling, palpitations.

Uncommon: congestive heart failure.

Respiratory, thoracic and mediastinal disorders

Common: shortness of breath.

Uncommon: eosinophilic pneumonia.

Gastrointestinal disorders

Common: constipation, abdominal pain, dyspepsia, nausea, diarrhea, stomatitis, flatulence.

Uncommon: gastrointestinal bleeding and/or gastric perforation, hematemesis, melena, vomiting.

Very rare: relapse or exacerbation of ulcerative colitis or Crohn’s disease.

Frequency unknown: gastritis.

Disorders of the liver and biliary tract

Uncommon: increased activity of liver enzymes, jaundice.

Skin and subcutaneous tissue disorders

Common: skin itching, skin rash, ecchymosis, purpura.

Uncommon: alopecia, photodermatoses.

Very rare: bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.

Musculoskeletal and connective tissue disorders

Uncommon: myalgia and muscle weakness.

Renal and urinary tract disorders

Uncommon: glomerulonephritis, hematuria, interstitial nephritis, nephrotic syndrome, renal failure, renal papillary necrosis.

General and administration site disorders

Common: thirst, increased sweating.

Uncommon: hypersensitivity reactions, menstrual irregularities, hyperthermia (chills and fever).

Edema and symptoms of heart failure and increased blood pressure have been reported during NSAID therapy.

Clinical studies and epidemiological data suggest that the use of some NSAIDs (especially high doses and long-term therapy) may be associated with a small increase in the risk of arterial thrombosis (eg, myocardial infarction or stroke).

Undesirable effects for which a cause-and-effect relationship with the use of naproxen has not been established

Blood and lymphatic system disorders: aplastic anemia, hemolytic anemia.

Nervous system disorders: aseptic meningitis, cognitive dysfunction.

Skin and subcutaneous tissue disorders: erythema multiforme, photosensitivity reactions similar to porphyria cutanea tarda and epidermolysis bullosa, urticaria.

Vascular disorders: vasculitis.

General disorders and disorders at the injection site: angioedema, hyperglycemia, hypoglycemia.

If you notice such phenomena, stop taking the drug and, if possible, consult a doctor.

Interaction

When treating with anticoagulants, be aware that naproxen may prolong bleeding time. Theraliv 275 should not be used simultaneously with acetylsalicylic acid or other NSAIDs, including selective cyclooxygenase-2 inhibitors (increased risk of side effects).

Patients concomitantly receiving hydantoins, anticoagulants, or other drugs that are significantly bound to plasma proteins should be monitored for signs of potentiation of action or overdose of these drugs.

Theraliv 275 may reduce the antihypertensive effects of propranolol and other beta-blockers, and may also increase the risk of renal failure associated with the use of angiotensin-converting enzyme (ACE) inhibitors.

NSAIDs may reduce the diuretic effect of diuretics. Naproxen inhibits the natriuretic effect of furosemide. Diuretics may increase the risk of NSAID nephrotoxicity.

Inhibition of renal clearance of lithium leads to an increase in plasma lithium concentrations. Taking probenecid increases the plasma concentration of naproxen. Cyclosporine increases the risk of developing renal failure.

Naproxen slows down the excretion of methotrexate, phenytoin, and sulfonamides, increasing the risk of developing their toxic effects.

Antacids containing magnesium and aluminum reduce the absorption of naproxen.

Myelotoxic drugs increase the manifestations of hematotoxicity of the drug.

According to in vitro studies, the simultaneous use of naproxen and zidovudine increases the concentration of zidovudine in the blood plasma.

Concomitant use of corticosteroids may increase the risk of GI ulceration or bleeding.

NSAIDs may enhance the effect of anticoagulants such as warfarin.

The simultaneous use of naproxen and antiplatelet drugs, selective serotonin reuptake inhibitors increases the risk of gastrointestinal bleeding.

Concomitant use of NSAIDs is not recommended for 8-12 days after using mifepristone.

Concomitant use of NSAIDs and tacrolimus increases the risk of nephrotoxicity.

Overdose

Symptoms

A significant overdose of naproxen may be characterized by drowsiness, dyspeptic disorders (heartburn, nausea, vomiting, abdominal pain), weakness, tinnitus, irritability, and in severe cases, hematemesis, melena, impaired consciousness, convulsions and renal failure.

Treatment

A patient who has accidentally or intentionally taken a large amount of Theraliv 275 needs to lavage the stomach, take activated charcoal and undergo symptomatic therapy: antacids, H2 receptor blockers, proton pump inhibitors. Hemodialysis is ineffective.

Recommendations for use

Inside. The tablets should be taken with enough water.

Adults and children 15 years and older

Typically, the daily dose used to relieve pain is 2-3 tablets (550-825 mg). The maximum daily dose is 3 tablets (825 mg). Duration of use – no more than 5 days.

When using Theraliv 275 as an antipyretic, the initial dose is 2 tablets, then 1 tablet (275 mg) is taken every 8 hours.

For the prevention and treatment of migraine attacks, the initial recommended dose is 2 tablets (550 mg), if necessary, you can take 1 tablet (275 mg) every 8-12 hours. The maximum daily dose is 3 tablets (825 mg).

To relieve menstrual pain and cramps, pain after insertion of intrauterine devices and other gynecological pain, it is recommended to prescribe the drug in an initial dose of 2 tablets (550 mg), then 1 tablet (275 mg) every 8 hours.

Children

Theraliv 275 is contraindicated for use in children under 15 years of age.

Elderly patients (≥ 65 years)

Patients over 65 years of age should take the drug as needed every 12 hours.

To reduce the risk of developing adverse events from the gastrointestinal tract, the drug should be taken in the minimum effective dose for the shortest possible short course.

If you feel that the effect of the drug is very strong or weak, tell your doctor or pharmacist.

Functional features

Quickly and completely absorbed from the gastrointestinal tract. Bioavailability – 95% (food intake has virtually no effect on either the completeness or the rate of absorption). Time to reach maximum concentration is 1-2 hours. Plasma protein binding > 99%. The half-life is 12-15 hours. Metabolism occurs in the liver to dimethylnaproxen with the participation of the CYP2C9 isoenzyme. Clearance – 0.13 ml/min/kg. 98% is excreted by the kidneys, 10% is excreted unchanged, with bile – 0.5-2.5%. The equilibrium concentration in the blood plasma is determined after taking 4-5 doses of the drug (2-3 days).

In case of renal failure, accumulation of metabolites is possible.

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after expiration date.

Manufacturer

Bayer Bitterfeld GmbH, Germany